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Expression of TAP73 and ANP73 in malignant gliomas 
Abstract. The p73 gene is able to encode transcriptionaly 
active TAp73, as well as a dominant-negatively acting ANp73 
transcript isoforms. We studied differential expression of 
these forms in normal brain as well as glial tumors, by semi­
quantitative RT-PCR. The expression of p73 was low or 
undetectable in normal brain tissues. Most of the tumors 
and non-tumor brain tissues also lacked significant 
expression of p73 in patients with low-grade astrocytomas. In 
contrast, most high-grade glial tumors displayed strong up-
regulation of TAp73, whereas only a few displayed ANp73 
expression. These aberrations may reflect the inactivation of 
retinoblastoma pathway in these tumors which result in the 
activation of E2F transcription factors, since TAp73 is a known 
target of E2F1 gene. The study of TAp73 expression in brain 
tumors may serve as a means to evaluate the retinoblastoma 
pathway-dependent tumor progression. 
Introduction 
Malignant gliomas are the most prevalent primary neuro­
ectodermal tumors, accounting for 15-23% of intracranial 
tumors and about 50% of all primary brain tumors in adults 
(1). The World Health Organization classifies these tumors, 
which arise from supportive glial cells of the central nervous 
system, into four grades of malignancy in the increasing 
order from I to IV (2). Despite technological improvements 
in neurodiagnostics, neurosurgery and adjuvant therapy, 
there has been little improvement in the survival rates of 
the patients with malignant gliomas. For example, the mean 
survival rate for astrocytoma grade IV (glioblastoma multi­
forme) is less than one year (3). Current therapies have limited 
impact on the mortality rate of malignant gliomas for several 
reasons. First, these tumors diffusely infiltrate the brain to 
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render complete resection impossible. Second, they are 
resistant to conventional chemotherapy because of blood-
brain barrier that limits the penetration of drugs into the 
brain. Finally, radiotherapy is limited to low dose irradiations 
because of its harmful effects to the normal brain tissue at 
high doses (4). Thus, it is necessary to develop new therapeutic 
strategies for these incurable tumors and this will only be 
possible once a thorough understanding as to their behavior 
and biology have been achieved. 
The p53 gene is the most frequently mutated tumor 
suppressor gene in human cancers (5). Germline mutations of 
p53 gene are known to lead to Li-Fraumeni syndrome, which 
harbors the carcinoma of brain in the tumor spectrum of these 
patients (6). Moreover, allelic loss of p53 locus was described 
as an early event in gliomagenesis and p53 gene mutations 
were shown to be present at 30-50% of astrocytic tumors 
(7,8). Thus, inactivation of p53 is a common event in glial 
tumor formation. The p53 protein, together with p63 and p73, 
forms a family of transcription factors. The p73 gene was 
identified as the first p53 homologue (9). The structural 
and functional similarities of p53 and p73 proteins confer a 
probable tumor suppressor function for the new family member 
(10,11). However, in contrast to p53, p73 mutations are rare 
if not absent in different cancers including the tumors of the 
brain (10). Nevertheless, p73 gene display aberrant changes in 
its expression patterns in tumors suggesting its involvement 
in malignancy in an unusual manner. The p73 gene has an 
unusual ability to express multiple transcript forms resulting 
from either alternative splicing or alternative promoter usage. 
In addition to TAp73 and ANp73 isoforms generated by 
alternative promoter usage, 10 different isoforms generated 
by alternative splicing have been identified so far (11,12). All 
these isoforms encode different protein products that are able 
to form hetero-oligomers and tetramers as they all contain an 
oligomerization domain (9). The transcriptionally active full-
length TAp73 and the dominant-negative ANp73 display 
opposite activities. TAp73 induces cell-cycle arrest and 
apoptosis, whereas ANp73 inhibits both TAp73- and p53-
induced apoptosis. Furthermore, ANp73 is induced by TAp73 
and p53, creating a dominant-negative feedback loop that 
regulates p53 and p73 function (12-14). 
The ANp73 isoform is generated by the usage of an internal 
promoter and an additional exon within the intron 3 of human 
p73 gene (13,15,16). The putative protein product of this novel 
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transcript (ANp73) lacks the transactivation (TA) domain that 
is present in TAp73. This truncation confers to the ANp73 
the ability to inhibit the transcriptional activities of both 
wild-type p53 and TAp73 proteins (13,16-18). The ANp73 
transcripts were shown to be the major p73 gene product in 
mouse tissues during development and adulthood (17). In vitro 
overexpression of ANp73 was shown to inhibit p53-dependent 
apoptosis in nerve cells following NGF withdrawal (18). 
There are no functional studies describing a probable function 
for ANp73 in glial cells. However, p53 and ANp73 complexes 
were shown to be present in the mouse brain (18). 
A large number of p73 expression studies in different 
tumors have been conducted, but there are very few reports 
about the relative expressions of TAp73 and ANp73 
transcripts/proteins in human malignancies. In primary 
hepatocellular carcinomas (HCCs) and HCC-derived cell 
lines, ANp73 levels were shown to be in comparable amounts 
with that of normal liver, whereas TAp73 expression was up-
regulated (15). A recent report describes an overexpression 
of ANp73 transcript and protein in primary breast carcinoma 
samples (19). The status of p73 gene in neuroblastomas is of 
particular interest, since the loss of chromosomal locus lp36 
where p73 gene resides and N-myc amplification is strongly 
associated with poor prognosis in these tumors (20). In 
addition, the expression of ANp73 transcript was described in 
30% of neuroblastoma samples which display a poor prognosis 
(21). In another study both TAp73 and ANp73 transcripts were 
defined to be present in neuroblastic tumors (22). However, 
to our knowledge, the relative expression of TAp73 and ANp73 
transcripts in glial tumors has not been reported yet. 
In this study, we analyzed the relative expression of TAp73, 
in comparison with ANp73 isoform in normal brain tissues, 
as well as in glial tumors using semi-quantitative RT-PCR 
methods. Our data show that these p73 transcipts are low or 
undetectable in normal human brain tissues as well as early 
stage glial tumors, whereas most advanced glial tumors express 
the TAp73 form, and occasionally the ANp73 transcripts. 
Materials and methods 
Tumor and tissue samples. All tumor and tissue samples 
were obtained at surgery. Freshly collected samples were 
immediately frozen and stored in liquid nitrogen prior to 
analysis. Normal brain samples (n=3) were obtained as 
discarded materials from anterior temporal lobectomies in 
amygdalohippocampectomy surgeries applied for surgical 
therapy of epilepsy. A total of 20 tumor samples were also 
collected together with 9 available corresponding non-tumor 
tissues (Table I). Tumor and tissue samples were sliced using 
a microtome, stained with hematoxylin-eosin and were 
evaluated by two different pathologists. Tumor tissues 
containing more than 80% tumor positive nuclei and non-tumor 
tissues with no tumor contamination were selected for further 
studies. 
RNA extraction. Total RNA from tumor and normal tissues 
were extracted using TriPure reagent (Boehringer Mannheim, 
IN, USA), as described by the supplier. Following column 
purification and DNase treatment (MN RNA Quickspin II, 
Duren, Germany), 5 u.g total RNA was used to prepare cDNA 
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using RevertAid First Strand cDNA Synthesis Kit (MBI-
Fermentas, Vilnius, Lithuania). 
Semi-quantitative PCR. The quality and the quantity of cDNA 
were initially tested by GAPDH RT-PCR amplification with 
primer pair GAPDH-F (5'-GGCTGAGAACGGGAAGCT 
TGTCAT-3') and GAPDH-R (5'-CAGCCTTCTCCATGG 
TGGTGAAGA-3'), using 1/20 and 1/40 volume of cDNA 
preparation. Further PCR studies were performed with cDNA 
preparations yielding equal amounts of GAPDH amplification 
products. For the semi-quantitative PCR analysis of each 
transcript (TAp73 and ANp73), the optimum number of PCR 
cycles have been defined following an initial study at 22, 26, 
30, 34 and 37 cycles, in order to remain in the logarithmic 
phase of amplification. All RT-PCR results have been repeated 
several times from different batches of cDNA preparations 
and TAp73 and ANp73 transcripts were tested with 2 different 
primer sets. Appropriate positive and negative controls were 
used in all experiments. For the detection of TAp73 and 
potential N-terminal alternatively spliced forms (13,23), two 
sets of primers were used. Primers and PCR conditions 
described by Fillippovich et al were used initially (23). Later, 
the same set of tissue and tumor samples were tested using 
another primer set composed of a forward primer from 
exon 1 (P73X1F: CCAGGCCAGCCGGGACGGA) and a 
reverse primer from exon 5 (p73X5R: CTTGGCGATCTGG 
CAGTAGA). The expression profile of ANp73 transcript was 
also assayed by using 2 different primer pairs, one using the 
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Figure 1. Differential expression of TAp73 and ANp73 in normal brain and 
malignant gliomas. The expression of TAp73 and ANp73 in (A), normal brain 
and non-tumor tissues; (B), low-grade tumor samples and (C), high-grade 
tumor samples. The expression of p73 transcript isoforms was performed 
semi-quantitatively, using GAPDH as a control. Asterisk denotes the PCR 
band corresponding to a minor p73 transcript isoform (A2) that lacks exon 2 
(see text). 
same PCR conditions and primers described at Sayan et al (15) 
and another using a forward primer at exon 3 (p73-NDNF: 
GCTGTACGTCGGTGACCCC) and a reverse at exon 5 
(p73X5R). The PCR conditions and additional information is 
available upon request. 
Densitometric analysis of transcripts. The ethidium bromide-
stained agarose gel pictures were captured by Bio-Rad Gel 
Doc 2000 system and analyzed by NIH-Scion Image analysis 
program. Following a background reduction, the crude 
absorption of the bands was calculated. The samples were 
normalized with the corresponding GAPDH values. Next, the 
maximum values registered with normal brain samples for 
each class of transcripts were calculated. Then, we calculated 
the ratio of each sample value to that maximum value 
observed in normal brain. The ratio of 3.0 or higher was chosen 
arbitrarily as a significant increase. 
Results 
The differential expression of TAp73 and ANp73 transcript 
isoforms in normal and diseased brain tissues was analyzed 
using two separate primer pairs for each isoform, as described 
in Materials and methods. The results obtained by these 
alternative primer pair combinations were essentially similar 
for both TAp73 and ANp73 isoforms. The data obtained with 
primer pairs described in Fillippovich et al (23) for TAp73 
isoform and Sayan et al (15) for ANp73 isoform are presented 
in Fig. 1, as an example. 
The expression ofTAp73 and ANp73 gene in non-tumor brain 
tissues. We used 12 tissues for this purpose. Three samples 
from non-cancer patients were used as normal brain tissues. 
As shown in Fig. 1A, these normal tissues did not express 
detectable levels of p73 transcripts under semi-quantitative 
PCR conditions (see Materials and methods). Under these 
conditions, 9 additional non-tumor brain tissues were also 
negative, except for 2 tissues that showed weak TAp73 
expression (Fig. 1 A). In order to quantify the changes in the 
levels of TAp73 and ANp73 under different conditions, we 
compared the densitometric intensities of the PCR bands as 
explained in Material and methods. Using the normal brain 
as a background reference, a ratio of 3.0-fold or higher was 
set arbitrarily as a significant increase. Accordingly, the TAp73 
levels were determined to be positive in non-tumor samples 
NT11 and NT13, with ratios 3.0 and 5.2 respectively (Fig. 1A). 
The expression of TAp73 and ANp73 gene in low-grade 
versus high-grade glial tumors. A total of 20 brain tumors 
were tested. Low-grade tumor group consisted of 8 samples 
(Table I). Similar to non-tumor brain samples, these low-grade 
tumors did not display a significant expression of TAp73 or 
ANp73 transcripts, with the exception of one tumor (G16) 
that displayed a ratio of 3.1 for TAp73 (Fig. IB). In sharp 
contrast with these low-grade tumors, most of the high-grade 
glial tumors displayed increased levels of TAp73 (Fig. 1C). A 
significant increase (ratio 3.0 or higher) of TAp73 was 
detectable in eight out of 12 tumors (67%). In some tumors 
(i.e., Gl, G8, G14), this increase was more than 10-fold, when 
compared to normal brain (data not shown). The ANp73 levels 
were also increased, but only in 3/12 (25%) of these high-
grade glial tumors (Fig. 1C). It was noted that a faster 
migrating PCR band was also detectable with TAp73 in some 
high-grade tumors (shown with asterisk in Fig. 1C). Nucleic 
acid sequencing revealed that this weakly positive band 
represents the N-terminal alternatively spliced D2 form 
lacking the exon 2 sequence (11) co-amplifying with TAp73 
sequences (data not shown). 
Discussion 
We report here that p73 gene expression in normal human 
brains is undetectable under semi-quantitative PCR conditions. 
Similarly, most brain tissues from patients with low-grade 
glial tumors also lack significant p73 expression. In contrast, 
the expression of p73 is induced in most high-grade glial 
tumors that display increased levels of TAp73 transcripts. 
This increase in TAp73 levels is accompanied with a 
concomitant increase in the levels of ANp73, in some but not 
all tumors. Although the differential expression of p73 
isoform in these cancers has not been reported previously, 
Loiseau et al (24) defined a grade-dependent increase of total 
p73 transcripts in astrocytic tumors as compared to non-
tumor samples. Dong et al (25) have also reported that total 
p73 transcript levels were increased in some astrocytic 
tumors, although they also reported a decrease in some other 
High-grade glial tumors 
Low-grade glial tumors 
Normal Non-tumor tissue from patients 
1340 UGUR et al; TAP73 AND ANP73 IN MALIGNANT GLIOMAS 
tumors. Kamiya and Nakazoto studied the expression of p73 
by immunohistochemistry and reported an increase in p73 
protein label ing index in grade IV astrocytomas when 
compared to grade I, II and III astrocytomas (26). Thus, in 
agreement with these studies, our observations provide 
additional evidence that the expression of p73 gene is indeed 
induced in advanced glial tumors. 
More importantly, we demonstrate that the induction of 
p73 gene expression in advanced glial tumors results in the 
production of the transcriptionally active TAp73 isoform in 
most cases, although additional forms including ANp73 and 
D2 isoforms are also detected in some of these tumors. As 
stated earlier, the protein encoded by TAp73 is a pro-apoptotic 
and growth-inhibitory molecule, whereas ANp73 transcripts 
encode oppositely-acting anti-TAp73 and anti-p53 molecules 
(11,13,16). Therefore, it may appear quite surprising that it is 
the TAp73 rather than ANp73 that is up-regulated in glial 
tumors, as they evolve from low- to high-grade tumors. We 
believe that this pattern of p73 expression may reflect the 
implication of a well-described oncogenic pathway in glioma-
genesis. One of the dysregulations during gliomagenesis, 
especially in astrocytoma-derived tumors, is the disruption of 
the retinoblastoma pathway. It has been clearly established 
that the transformation from low to intermediate-grade 
gliomas (anaplastic astrocytomas) is accompanied by allelic 
losses on chromosomes 9p and 13q, and less frequently by 
12q amplification. The allelic losses involve the inactivation 
of RBI and pl6 I N K 4 A genes, whereas the 12q amplification 
reflects the amplification of cyclin-dependent kinase 4 (27). 
Experimental evidence demonstrates that the inactivation of 
the retinoblastoma pathway causes an abnormal activation of 
E2F transcription factors acting as key positive regulators of 
cell cycle progression from Gl to S phase (28). Oncogenic 
activation of E2F1 also results in the induction of TA-p73, by 
the positive regulation of the first promoter of the p73 gene 
(29). The alternative promoter of p73 which drives the 
expression of ANp73 is not controlled by E2F1, although it is 
responsive to TAp73 protein (12-14). Thus, the induction of 
TAp73 in advanced gliomas correlates with the inactivation 
of retinoblastoma pathway which occurs in intermediate-
grade tumors. In support of this hypothesis, we observed in a 
retinoblastoma-deficient cell line (Hep3B) that ectopically-
introduced E2F1 induces the expression of endogenous 
TAp73, followed by a weaker induction of ANp73 expression 
(Karakuzu O et al, unpublished data). 
Although we do not know whether the TAp73 expression 
affects the behavior of malignant gliomas, it is noteworthy 
that the inactivation of p53 tumor suppressor gene is an early 
event in gliomagenesis. In human gliomas, p53 mutations are 
primarily missense mutations and target the evolutionarily 
conserved domains in exons 5, 7, and 8, thus affecting 
residues that are crucial to DNA binding (27). As some mutant 
p53 molecules were shown to effectively inhibit the activity 
of TAp73 protein, malignant glioma cells could use mutant 
p53 protein to antagonize tumor suppressor functions of TAp73 
protein (30). 
Taken together our observations provide indirect evidence 
that, glioma tumors up-regulate the expression of TAp73 in 
relation with the inactivation of the retinoblastoma pathway 
in these tumors. Thus, the study of TAp73 expression in these 
malignancies can serve as a marker for tumor progression. 
This could be particularly important for the selection of patients 
for new therapeutic trials aiming to kill selectively gliomas 
displaying retinoblastoma pathway inactivation (31). It is not 
clear whether the increase of TAp73 transcripts is associated 
with a concomitant accumulat ion of TAp73 protein in 
advanced gliomas. However, it appears that, even if it is 
present in these tumors, it must be in a dormant/inactive 
state, probably by mutant p53 proteins and/or dominant 
negative p73 gene derived proteins. However, TAp73 protein 
was shown to be activated by some chemical drugs. Therefore, 
it would be interesting to test whether the TAp73 protein 
could be used as a target for glioma therapy by drug-induced 
activation of its pro-apoptotic functions (32). 
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